<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32651161</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>102844</StartPage><MedlinePgn>102844</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102844</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2020.102844</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(20)30219-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Low-dose interleukin-2 (ld-IL-2) enhances regulatory T-cell (Treg) function in auto-inflammatory conditions. Neuroinflammation being a pathogenic feature of amyotrophic lateral sclerosis (ALS), we evaluated the pharmacodynamics and safety of ld-IL-2 in ALS subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a single centre, parallel three-arm, randomised, double-blind, placebo-controlled study. Eligibility criteria included age &lt;&#xa0;75 years, disease duration &lt;&#xa0;5 years, riluzole treatment &gt;&#xa0;3 months, and a slow vital capacity &#x2265;&#xa0;70% of normal. Patients were randomised (1:1:1) to aldesleukin 2 MIU, 1 MIU, or placebo once daily for 5 days every 4 weeks for 3 cycles. Primary outcome was change from baseline in Treg percentage of CD4<sup>+</sup> T cells (%Tregs) following a first cycle. Secondary laboratory outcomes included: %Treg and Treg number following repeated cycles, and plasma CCL2 and neurofilament light chain protein (NFL) concentrations as surrogate markers of efficacy. Safety outcomes included motor-function (ALSFRS-R), slow vital capacity (SVC), and adverse event reports. This trial is registered with ClinicalTrials.gov, NCT02059759.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">All randomised patients (12 per group), recruited from October 2015 to December 2015, were alive at the end of follow-up and included in the intent-to-treat (ITT) analysis. No drug-related serious adverse event was observed. Non-serious adverse events occurred more frequently with the 1 and 2 MIU IL-2 doses compared to placebo, including injection site reactions and flu-like symptoms. Primary outcome analysis showed a significant increase (p&#xa0;&lt;&#xa0;0&#xb7;0001) in %Tregs in the 2 MIU and 1 MIU arms (mean [SD]: 2 MIU: +6&#xb7;2% [2&#xb7;2]; 1 MIU: +3&#xb7;9% [1&#xb7;2]) as compared to placebo (mean [SD]: -0&#xb7;49% [1&#xb7;3]). Effect sizes (ES) were large in treated groups: 2 MIU ES=3&#xb7;7 (IC95%: 2&#xb7;3-4&#xb7;9) and 1 MIU ES=3&#xb7;5 (IC95%: 2&#xb7;1-4&#xb7;6). Secondary outcomes showed a significant increase in %Tregs following repeated cycles (p&#xa0;&lt;&#xa0;0&#xb7;0001) as compared to placebo, and a dose-dependent decrease in plasma CCL2 (p&#xa0;=&#xa0;0&#xb7;0049). There were no significant differences amongst the three groups on plasma NFL levels.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Ld-IL-2 is well tolerated and immunologically effective in subjects with ALS. These results warrant further investigation into their eventual therapeutic impact on slowing ALS disease progression.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">The French Health Ministry (PHRC-I-14-056), EU H2020 (grant #633413), and the Association pour la Recherche sur la SLA (ARSLA).</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Clinique du Motoneurone, CHU Gui de Chauliac, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mickunas</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, UK; NIHR Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veyrune</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Cell and Tisue Engineering, University of Montpellier, CHU Montpellier, Montpellier France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payan</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), N&#xee;mes University Hospital, N&#xee;mes, France; Department of Pharmacology, AP-HP.Sorbonne Universit&#xe9;, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, 47, Bd de l'H&#xf4;pital, F-75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garlanda</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Clinical &amp; Research Institute, Milan, Italy; Humanitas University, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locati</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Clinical &amp; Research Institute, Milan, Italy; Department of Medical Biotechnologies and Translational Medicine, University Milan, Milan Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juntas-Morales</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinique du Motoneurone, CHU Gui de Chauliac, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pageot</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinique du Motoneurone, CHU Gui de Chauliac, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience and Trauma Centre, Institute of Cell and Molecular Medicine, Department of Neuroimmunology, Barts and the London School of Medicine and Dentistry, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Neurochemistry, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suehs</LastName><ForeName>Carey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Medical Information and Respiratory Diseases, University of Montpellier, CHU Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saker</LastName><ForeName>Safa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>DNA and Cell Bank, Genethon, Evry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masseguin</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Delegation for Clinical Research and Innovation, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vos</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Tisue Engineering, University of Montpellier, CHU Montpellier, Montpellier France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Neurochemistry, University of Gothenburg, M&#xf6;lndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry Psychology and Neuroscience, Department of Basic and Clinical Neuroscience, King's College London, London, UK; Department of Neurology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leigh</LastName><ForeName>P Nigel</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>The Trafford Centre for Biomedical Research, Brighton and Sussex Medical School, Falmer, Brighton BN1 9RY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tree</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, UK; NIHR Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. Electronic address: timothy.tree@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bensimon</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), N&#xee;mes University Hospital, N&#xee;mes, France; Department of Pharmacology, AP-HP.Sorbonne Universit&#xe9;, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, 47, Bd de l'H&#xf4;pital, F-75013 Paris, France; Department of Pharmacology, Sorbonne Universit&#xe9; M&#xe9;decine, F-75013 Paris, France. Electronic address: gbensimon.psl@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02059759</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>M89N0Q7EQR</RegistryNumber><NameOfSubstance UI="C082598">aldesleukin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Low dose interleukin-2</Keyword><Keyword MajorTopicYN="N">Neuro-inflammation</Keyword><Keyword MajorTopicYN="N">Randomised clinical trial</Keyword><Keyword MajorTopicYN="N">Regulatory T cells</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Drs. Camu, Mickunas, Payan, Juntas Morales, Pageot, Masseguin, Suehs, De Vos, Saker, Andreasson and Veyrune have nothing to disclose. Dr. Bensimon reports grants from French Health Ministry (PHRC-I), ARSLA and EU HORIZON 2020, during the conduct of the study; in addition, Dr. Bensimon has a patent (WO 2012123381 A1) with royalties paid to Assistance Publique Hopitaux de Paris (APHP), Institut National de la Sante et de la Recherche Medicale INSERM, and Sorbonne Universite.&#xa0;Drs. Bensimon, Tree, Leigh, Locati, Garlanda, Shaw, Kirby, Malaspina have a patent (B75649EPD40021) pending. Dr. Malaspina reports grants from EU HORIZON 2020, grants from MND Association UK, grants and other from Barts and the London Charity, and from UCB Pharma SPRL, during the conduct of the study; and from F. Hoffmann-La Roche outside the submitted work.&#xa0;Dr. Zetterberg reports personal fees from Samumed, Roche Diagnostics, Denali, CogRx and Wave, outside the submitted work.&#xa0;Dr. Kirby reports grants from The Nimes University Hospital Center (CHU Nimes) and grants from EU HORIZON 2020, during the conduct of the study.&#xa0;Dr. Shaw reports grants from EU HORIZON 2020, Sheffield component and MIROCALS (633413), outside the submitted work.&#xa0;Dr. Al-Chalabi reports involvement as Chief Investigator for LEVALS clinical trial and European CI for REFALS clinical trial for OrionPharma, as well as consultancy from Mitsubishi Tanabe Pharma, consultancy and involvement in debating panel for Cytokinetics Inc, consultancy from Chronos Therapeutics, GSK, Lilly, and from Biogen Idec, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32651161</ArticleId><ArticleId IdType="pmc">PMC7502670</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2020.102844</ArticleId><ArticleId IdType="pii">S2352-3964(20)30219-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901. ALS/Riluzole Study Group.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg L.H., Sorenson E., Gronseth G., Macklin E.A., Andrews J., Baloh R.H. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2013;e1623. doi: 10.1212/WNL.0000000000007242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D., Van den Oord J.J., Vianney de Jong J.M. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 1990;16:401&#x2013;410. doi: 10.1111/j.1365-2990.1990.tb01276.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1990.tb01276.x</ArticleId><ArticleId IdType="pubmed">2263315</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu M.E., Kozovska M., Appel S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57:1282&#x2013;1289. doi: 10.1212/wnl.57.7.1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.57.7.1282</ArticleId><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Dedeene L., Goossens J., Claeys K.G., Van Den Bosch L. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2019;90:1338&#x2013;1346. doi: 10.1136/jnnp-2018-319586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff J.R., Beers D.R., Zhao W., Pleitez M., Simpson E.P., Berry J.D. Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5:e465. doi: 10.1212/NXI.0000000000000465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000465</ArticleId><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M.C., Couch Y., Sibson N., Turner M.R. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci. 2013;53:34&#x2013;41. doi: 10.1016/j.mcn.2012.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2012.10.008</ArticleId><ArticleId IdType="pubmed">23110760</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid S.I., Ampie L., Kelly R., Ladha S.S., Dardis C. Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front Neurol. 2017;8:486. doi: 10.3389/fneur.2017.00486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00486</ArticleId><ArticleId IdType="pmc">PMC5622209</ArticleId><ArticleId IdType="pubmed">28993751</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11:7&#x2013;13. doi: 10.1038/ni.1818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1818</ArticleId><ArticleId IdType="pubmed">20016504</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M., Evangelopoulos E., Sereti E., Zouvelou V., Marmara S., Alexakis T. Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol Scand. 2012;125:260&#x2013;264. doi: 10.1111/j.1600-0404.2011.01528.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2011.01528.x</ArticleId><ArticleId IdType="pubmed">21651502</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S., Garbelli S., Pasini A., Alimonti D., Perotti C., Melazzini M. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol. 2009;210:73&#x2013;79. doi: 10.1016/j.jneuroim.2009.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.02.012</ArticleId><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Beers D.R., Wen S., Rivera A.L., Toennis K.M., Appel J.E. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek T.R., Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665&#x2013;674. doi: 10.1038/nri1435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1435</ArticleId><ArticleId IdType="pubmed">15343366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorn E., Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108:1571&#x2013;1579. doi: 10.1182/blood-2006-02-004747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-02-004747</ArticleId><ArticleId IdType="pmc">PMC1895505</ArticleId><ArticleId IdType="pubmed">16645171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687&#x2013;697. doi: 10.1016/j.immuni.2008.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.03.016</ArticleId><ArticleId IdType="pmc">PMC2394854</ArticleId><ArticleId IdType="pubmed">18468463</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahvildari M., Dana R. Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J Immunol Baltim Md 1950. 2019;203:2749&#x2013;2755. doi: 10.4049/jimmunol.1900733.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1900733</ArticleId><ArticleId IdType="pmc">PMC6986328</ArticleId><ArticleId IdType="pubmed">31740549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartemann A., Bensimon G., Payan C.A., Jacqueminet S., Bourron O., Nicolas N. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1:295&#x2013;305. doi: 10.1016/S2213-8587(13)70113-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(13)70113-X</ArticleId><ArticleId IdType="pubmed">24622415</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J., Norgren N., Dobson R., Topping J., Nissim A., Malaspina A. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE. 2013;8:e75091. doi: 10.1371/journal.pone.0075091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075091</ArticleId><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M., Price R.W., Andreasson U., Norgren N., Nilsson S., Hagberg L. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: a Cross-Sectional Study. EBioMedicine. 2016;3:135&#x2013;140. doi: 10.1016/j.ebiom.2015.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.11.036</ArticleId><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Keselman H.J., Cribbie R., Holland B. The pairwise multiple comparison multiplicity problem: an alternative approach to familywise and comparison wise Type I error control. Psychol Methods. 1999;4:58&#x2013;69. doi: 10.1037/1082-989X.4.1.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1082-989X.4.1.58</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff J.R., Simpson E.P., Appel S.H. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor T., Borsig L., Heikenwalder M. CCL2-CCR2 Signaling in Disease Pathogenesis. Endocr Metab Immune Disord Drug Targets. 2015;15:105&#x2013;118. doi: 10.2174/1871530315666150316120920.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871530315666150316120920</ArticleId><ArticleId IdType="pubmed">25772168</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T., Nagano I., Shiote M., Narai H., Murakami T., Hayashi T. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res. 2007;29:772&#x2013;776. doi: 10.1179/016164107X229795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164107X229795</ArticleId><ArticleId IdType="pubmed">17672928</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammana S., Fagone P., Cavalli E., Basile M., Petralia M., Nicoletti F. The role of macrophages in neuroinflammatory and neurodegenerative pathways of alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis: pathogenetic cellular effectors and potential therapeutic targets. Int J Mol Sci. 2018;19:831. doi: 10.3390/ijms19030831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19030831</ArticleId><ArticleId IdType="pmc">PMC5877692</ArticleId><ArticleId IdType="pubmed">29533975</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B., Zhao W., Beers D.R., Henkel J.S., Appel S.H. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237:147&#x2013;152. doi: 10.1016/j.expneurol.2012.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677&#x2013;686. doi: 10.1016/j.it.2004.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2004.09.015</ArticleId><ArticleId IdType="pubmed">15530839</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Siddiqui S., Gabriely G., Lanser A.J., Dake B., Murugaiyan G. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122:3063&#x2013;3087. doi: 10.1172/JCI62636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava R., Shukla N. Attributes of alternatively activated (M2) macrophages. Life Sci. 2019;224:222&#x2013;231. doi: 10.1016/j.lfs.2019.03.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.03.062</ArticleId><ArticleId IdType="pubmed">30928403</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Merino L., Iridoy M., Galbete A., Rold&#xe1;n M., Rivero A., Acha B. Evaluation of chitotriosidase and CC-chemokine ligand 18 as biomarkers of microglia activation in amyotrophic lateral sclerosis. Neurodegener Dis. 2018;18:208&#x2013;215. doi: 10.1159/000490920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000490920</ArticleId><ArticleId IdType="pubmed">30134252</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiemessen M.M., Jagger A.L., Evans H.G., van Herwijnen M.J.C., John S., Taams L.S. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A. 2007;104:19446&#x2013;19451. doi: 10.1073/pnas.0706832104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0706832104</ArticleId><ArticleId IdType="pmc">PMC2148309</ArticleId><ArticleId IdType="pubmed">18042719</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter W., Goldman C.K., Casabo L., Nelson D.L., Greene W.C., Waldmann T.A. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol Baltim Md 1950. 1987;138:2917&#x2013;2922.</Citation><ArticleIdList><ArticleId IdType="pubmed">3106493</ArticleId></ArticleIdList></Reference><Reference><Citation>Piehl F., Kockum I., Khademi M., Blennow K., Lycke J., Zetterberg H. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler Houndmills Basingstoke Engl. 2018;24:1046&#x2013;1054. doi: 10.1177/1352458517715132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458517715132</ArticleId><ArticleId IdType="pubmed">28627962</ArticleId></ArticleIdList></Reference><Reference><Citation>de Flon P., Laurell K., Sundstr&#xf6;m P., Blennow K., S&#xf6;derstr&#xf6;m L., Zetterberg H. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurol Scand. 2019;139:462&#x2013;468. doi: 10.1111/ane.13078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13078</ArticleId><ArticleId IdType="pubmed">30740668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramchandani R., Schoenfeld D.A., Finkelstein D.M. Global rank tests for multiple, possibly censored, outcomes. Biometrics. 2016;72:926&#x2013;935. doi: 10.1111/biom.12475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/biom.12475</ArticleId><ArticleId IdType="pmc">PMC4960007</ArticleId><ArticleId IdType="pubmed">26812695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean R.K., McKay F.C., Cretney E., Bye C.R., Perera N.D., Tomas D. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75:681&#x2013;689. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>